TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study.
TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study.
复制标题
DOI：
10.1038/npjpcrm.2015.82
复制
发表时间：
2016-02-04
影响因子：
3.1
通讯作者：
Hellgren J
中科院分区：
文献类型：
--
作者：
Cardell LO;Olsson P;Andersson M;Welin KO;Svensson J;Tennvall GR;Hellgren J
过敏性鼻炎是一种全球性疾病，众所周知，它对生活质量和工作表现有影响。人们对其对社会的经济影响程度知之甚少。 TOTALL 研究使用代表整个瑞典劳动年龄人口的样本估算了过敏性鼻炎的总成本。一份针对过敏性鼻炎的调查问卷被邮寄给随机抽取的 18-65 岁瑞典居民。对医疗保健接触、药物、缺勤（缺勤）和出勤（工作能力下降）进行了评估，并计算了过敏性鼻炎的直接和间接成本。根据 ARIA 指南评估药物使用情况。总共 8,001 人中有 3,501 人 (44%) 回答了调查问卷，其中 855 人 (24%) 报告了过敏性鼻炎。过敏性鼻炎的平均每年直接和间接费用分别为 210.3 欧元和 750.8 欧元，每人每年的总费用为 961.1 欧元。出勤占总成本的 70%。与局部类固醇相比，抗组胺药的使用似乎过量，鼻减充血剂的使用量也高得惊人。瑞典有 950 万人口，每年因过敏性鼻炎造成的总费用估计为 13 亿欧元。这些出乎意料的高成本可能与疾病的高患病率以及之前经常被低估的间接成本有关。更好地遵守指导方针可能会减轻社会的经济负担。
Allergic rhinitis is a global illness with a well-recognised impact on quality of life and work performance. Comparatively little is known about the extent of its economic impact on society. The TOTALL study estimates the total cost of allergic rhinitis using a sample representing the entire Swedish population of working age. A questionnaire focused on allergic rhinitis was mailed out to a random population of Swedish residents, aged 18–65 years. Health-care contacts, medications, absenteeism (absence from work) and presenteeism (reduced working capacity at work) were assessed, and the direct and indirect costs of allergic rhinitis were calculated. Medication use was evaluated in relation to the ARIA guidelines. In all, 3,501 of 8,001 (44%) answered the questionnaire, and 855 (24%) of these reported allergic rhinitis. The mean annual direct and indirect costs because of allergic rhinitis were €210.3 and €750.8, respectively, resulting in a total cost of €961.1 per individual/year. Presenteeism represented 70% of the total cost. Antihistamines appear to be used in excess in relation to topical steroids, and the use of nasal decongestants was alarmingly high. The total cost of allergic rhinitis in Sweden, with a population of 9.5 million, was estimated at €1.3 billion annually. These unexpectedly high costs could be related to the high prevalence of disease, in combination with the previously often underestimated indirect costs. Improved adherence to guidelines might ease the economic burden on society.